\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage[flushleft]{threeparttablex}

\usepackage{float}

\begin{document}


\def\RunningAuthor{Kannan R et al.}
\firstPage{145}
\articleType{Original Article}
\receivedDate{11 Dec 2019}
\acceptedDate{03 Mar 2020}
\revisedDate{18 Feb 2020}
\journalVolume{2020, 11(SPL)}
\journalIssue{2}
\journalDoi{ijrps.v11iSPL2.2174}
\copyrightYear{2020}
\def\authorCount{8}
\def\affCount{1}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{Correlation With Disease Activity Score 28 (Das28) With Pulmonary Function Test In Rheumatoid Arthritis Patients}
\author{Rameshwar~R,  
            Srujith~C.~H,  
            Jagadeesan~M,  
            Mahendra~Kumar,  
            Prassana~Karthik~S,  
            Kannan~R\textsuperscript{*},  
            Magesh~Kumar~S, 
            Kavitha~M.~M~\\[5pt]{Departmentt of General Medicine, Saveetha Medical College, SIMATS, Chennai 605102, Tamilnadu, India}}

\begin{abstract}
Rheumatoid Arthritis (RA) is a chronic inflammatory disease of unknown etiology involving both small and large joints with many extra-articular manifestations. There may be a variety of pulmonary complications associated with RA based on its disease activity and levels of RF and anti-CCP titers. Pulmonary involvement may be seen at different levels of the respiratory system, with infection being the most common cause of mortality. Our study shows the association and degree of pulmonary involvement in patients with RA based on the pulmonary function test and its correlation with the DAS 28 score. The aim of our study was to assess the prevalence of pulmonary involvement in patients with Rheumatoid Arthritis. The study population was 100 patients with RA diagnosed based on the 2010 ACR/EULAR criteria following all the exclusion. The patients were subjected to a PFT on diagnosis and repeated at 6 and 18 months following treatment. In our study, there is a higher prevalence of pulmonary involvement seen in doing PFT, even in asymptomatic patients with RA when compared to other studies. Pulmonary complications occurring in patients with Rheumatoid Arthritis may be identified on doing a PFT or HRCT thorax. Pulmonary involvement carries significant mortality and morbidity. Disease duration and disease activity score 28 were found to have a significant association with pulmonary complications. Although our study brings out the incidence of higher risk of pulmonary involvement in patients with RA, more studies meta-analysis are required.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Rheumatoid Arthritis,\newline RA,\newline Pulmonary Function Test,\newline PFT,\newline Disease activity Score 28,\newline DAS28,\newline RF,\newline Anti-CCP
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Kannan~R~\\ Phone:\ +91-97100 71284~\\  Email:\ endork@yahoo.com 
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Rheumatoid Arthritis (RA) is a chronic inflammatory disease of unknown etiology characterized by joint swelling, joint tenderness and destruction of synovial joints predominantly affecting the small joints with other extra-articular manifestations leading to severe disability and premature mortality \unskip~\citep{708797:16804929,708797:16804923}. 

The prevalence of RA in the general population ranges from from0.5\% to 2\% \unskip~\citep{708797:16804910}. All races are affected and women are commonly affected. The onset of illness frequently occurs during the fourth and fifth decade \unskip~\citep{708797:16804920}. 

Although RA is considered a disease of the joints, a variety of extra-articular manifestations result in an effect of immune-mediated mechanism. In some cases, the production of Rheumatoid Factor (RF) with the formation of immune complexes that fix complement causes extra-articular manifestations \unskip~\citep{708797:16804910}. Pulmonary disease is an important extra-articular manifestation of RA with autopsy studies suggesting that it is the second most common cause of death (10 to 20\%) after infections \unskip~\citep{708797:16804926,708797:16804919}. It has been estimated that nearly 50\% of RA patients will develop some form of pulmonary abnormality during their lifetime \unskip~\citep{708797:16804915}. 

RA can potentially affect all compartments of the lung (airways, parenchyma, vascular) or may coexist with the involvement of the pleura \unskip~\citep{708797:16804922}. The mean age of onset of lung diseases is the fifth to the sixth decade \unskip~\citep{708797:16804927}. Smokers and patients with high titer of Rheumatoid Factor (RF) are at higher risk of developing pulmonary complications \unskip~\citep{708797:16804911}.

\textbf{Aim \& Objectives}

The primary aim of the study is to detect a pulmonary pattern in an asymptomatic patient with a pulmonary function test in Rheumatoid arthritis and improvement in pulmonary function test following treatment and its correlation with DAS28. The objectives of the present study were, to identify the prevalence of lung involvement in patients with RA, other factors contributing for pulmonary diseases in patients with RA, to evaluate the clinical and spirometric features of pulmonary abnormalities in diagnosed cases of RA and evaluate the impact of treatment on pulmonary abnormality detected in RA.\ensuremath{^{}}
    
\section{Materials and Methods}
This was a hospital-based observational and descriptive study enrolling 100 consecutive patients with RA attending the rheumatology outpatient department in the Saveetha Medical College Hospital, Chennai, Tamilnadu, India from 01/04/2017 to 31/11/2018. In this study, a sample size of 100 patients diagnosed with rheumatoid arthritis (according to THE ACR/EULAR 2010 CLASSIFICATION CRITERIA{\tt\string\ \unskip}) will be assessed on the basis of the pulmonary function test and DAS28 on the day of diagnosis. The measurements used in data analysis are (1) FVC\% (2) FEV1\% and (3) FEV1: FVC ratio. The FVC and FEV1 are reported as a measured volume in liters and as a percentage of the predicted or reference value for an individual of that age, height, gender and ethnicity. FEV1: FVC ratio was calculated from the measured volume in liters and then the percentage was taken. Done using a single spirometry machine then repeated after 6 months and 18months.

The study included all patients during the period of study between the age of 18-70 years, patients attending clinics of the Medicine and Rheumatology departments and individuals satisfying 2010 ACR/EULAR classification criteria for RA. Patients were excluded for, not giving consent, patients with malignancy, post-transplant and post-radiotherapy immune suppression (due to potential confounding effects on data analysis), active infection and HIV/AIDS, patients with signs and symptoms of respiratory diseases(Cough, SOB, chest, pain, sputum production, cyanosis, edema and clubbing), systemic pulmonary diseases, Smoker and ex-smoker, chest wall and spinal deformity and failure to produce acceptable and reproducible spirograms. 

\textbf{Study method }

Patients were confirmed to have RA according to the following 2010 ACR/EULAR criteria:

\textbf{Joint involvement}

Joints involved $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ Score

1 large joint $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 0

2-10 large joints $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 1

1-3 small joints $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 2

4-10 small joints  $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 3

{\textgreater}10 joints $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 5

\textbf{Serology}

Serology $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $  score

Negative rheumatoid factor and negative Anti-CCP $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 0

Low positive rheumatoid factor and negative Anti-CCP $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 2

High positive rheumatoid factor and negative Anti-CCP $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 3 

\textbf{Acute phase reactants}

Acute phase reactants $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ score

Normal ESR $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $  0

Abnormal ESR $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 1

\textbf{Duration of symptoms}

Duration of symptoms $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ score

{\textless}6 weeks $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 0

{\textgreater}6 weeks $\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash}\text{\textemdash} $ 1

A score of more than 6/10 was necessary to confirm that a patient had definite RA.\ensuremath{^{}}

\textbf{Assessments}

\textbf{Disease Characteristics}

In patients with RA, various disease characteristics like age, sex, duration, comorbidities, treatment history, ESR, Rheumatoid Factor and the presence of deformities were assessed. In patients with RA disease activity was assessed by the Disease Activity Score (DAS28), calculated by using characteristics of RA: swollen joints and tender joints, visual analog scale (VAS) and ESR. Online calculator \BreakURLText{http://www.das-score.nl} was used to calculate DAS28.

The following formula was used to calculate DAS:

$DAS28=0.56\times\sqrt{\left(28TJ\right)}+0.28\times\sqrt{\left(28SJ\right)}+0.70\times LN\left(ESR\right)+0.014\times VAS $

(TJ = tender joints; SJ= swollen joints; VAS= patients general health on a visual analog scale)

A DAS28 score of {\textgreater}5.1 was considered to be high disease activity, a DAS28 score between 5.1 and 3.2 is considered moderate disease activity, a DAS28 score between 2.6 to 3.2 is considered low disease activity and DAS28 score below 2.6 considered remissions.

\textbf{Assessment of Pulmonary Involvement}

All the patients were evaluated with the history of previous diseases, pulmonary symptoms such as cough and phlegm, dyspnea, chest pain and wheezing. The Laboratory tests requested for the patients included: assessment of Rheumatoid Factor (RF), Erythrocyte Sedimentation Rate (ESR) and Anti-Cyclic Citrullinated Peptide (Anti CCP). 

\textbf{Statistics analysis}

Descriptive statistics such as percentage, mean, standard deviation and median were used to describe the variables used in the study. Quantitative and qualitative data were analyzed using t-tests and chi-square tests, respectively. Logistic regression was used to calculate the Odds Ratio (OR) and confidence interval of the variables. \textit{P} values less than 0.05 were considered statistically significant. 
    
\section{Results and Discussion}
On day 1, 75\% of patients were normal, 22\% of patients were restrictive and 3\% of patients were obstructive. After 6 months, 78\% of patients were normal, 19\% of patients were restrictive and 3\% of patients were obstructive. After 2 years, 85\% of patients were normal, 12\% of patients were restrictive and 3\% of patients were obstructive. The comparison was made by the chi-square test. The results showed that there is no significant difference in pulmonary function tests with respect to time (p=0.456).


\begin{table*}[!htbp]
\caption{\boldmath {Age Distribution} }
\label{tw-facc8f9cf44a}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2954\linewidth-2\tabcolsep}p{\dimexpr.3127\linewidth-2\tabcolsep}p{\dimexpr.3919\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Age  & \cAlignHack No. of cases  & \cAlignHack Percentage \\
\tblmidrule 
\cAlignHack {\textless}30 years  &
  \cAlignHack 7  &
  \cAlignHack 7\% \\
\cAlignHack 30-50 years  &
  \cAlignHack 58  &
  \cAlignHack 58\% \\
\cAlignHack {\textgreater}50 years  &
  \cAlignHack 35  &
  \cAlignHack 35\% \\
\cAlignHack Total  &
  \cAlignHack 100  &
  \cAlignHack 100\% \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The majority of patients were between 30-50 years (58\%). 35\% of patients were more than {\textgreater}50 years and 7\% of patients were less than {\textless}30 years}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Sex Distribution} }
\label{tw-1374b2acf546}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.34550000000000004\linewidth-2\tabcolsep}p{\dimexpr.33\linewidth-2\tabcolsep}p{\dimexpr.32449999999999996\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Sex Distribution  & \cAlignHack No. of cases  & \cAlignHack Percentage \\
\tblmidrule 
\cAlignHack Male  &
  \cAlignHack 11  &
  \cAlignHack 11\% \\
\cAlignHack Female  &
  \cAlignHack 89  &
  \cAlignHack 89\% \\
\cAlignHack Total  &
  \cAlignHack 100  &
  \cAlignHack 100\% \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The maximum numbers of patients were females (89\%). 11\% of the patientswere males}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Duration of Illness} }
\label{tw-3d76b6db3fc8}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.3664\linewidth-2\tabcolsep}p{\dimexpr.30570000000000004\linewidth-2\tabcolsep}p{\dimexpr.3279\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Duration of Illness  & \cAlignHack No. of cases  & \cAlignHack Percentage \\
\tblmidrule 
\cAlignHack {\textless}5 years  &
  \cAlignHack 45  &
  \cAlignHack 45\% \\
\cAlignHack {\textgreater}=5 years  &
  \cAlignHack 55  &
  \cAlignHack 55\% \\
\cAlignHack Total  &
  \cAlignHack 100  &
  \cAlignHack 100\% \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The maximum number of patients had the illness for more than 5 years (55\%). 45\% of patients had an illness for less than 5 years}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Treatment History} }
\label{tw-2f69782869cd}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.3456\linewidth-2\tabcolsep}p{\dimexpr.3144\linewidth-2\tabcolsep}p{\dimexpr.34\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Treatment History  & \cAlignHack No. of Cases  & \cAlignHack Percentage \\
\tblmidrule 
\cAlignHack Steroids &
  \cAlignHack 90  &
  \cAlignHack 90\% \\
\cAlignHack Methotrexate &
  \cAlignHack 80  &
  \cAlignHack 80\% \\
\cAlignHack Sulphasalazine &
  \cAlignHack 60  &
  \cAlignHack 60\% \\
\cAlignHack HCQ  &
  \cAlignHack 50  &
  \cAlignHack 50\% \\
\cAlignHack NSAIDs  &
  \cAlignHack 10  &
  \cAlignHack 10\% \\
\cAlignHack Vit D+C  &
  \cAlignHack 60  &
  \cAlignHack 60\% \\
\cAlignHack Leflunomadie  &
  \cAlignHack 10  &
  \cAlignHack 10\% \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The majority of patients had Steroids (90\%), 80\% of patients had Methotrexate and 50\% of patients had HCQ}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Rheumatoid Factor (RF)} }
\label{tw-d852d638b670}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.36980000000000004\linewidth-2\tabcolsep}p{\dimexpr.3127\linewidth-2\tabcolsep}p{\dimexpr.3175\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Rheumatoid Factor & \cAlignHack No. of Cases & \cAlignHack Percentage\\
\tblmidrule 
\cAlignHack Positive &
  \cAlignHack 87 &
  \cAlignHack 87\%\\
\cAlignHack Negative &
  \cAlignHack 13 &
  \cAlignHack 13\%\\
\cAlignHack Total &
  \cAlignHack 100 &
  \cAlignHack 100\%\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{Out of 100 patients, most of them had a positive Rheumatoid factor (87\%)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Anti CCP} }
\label{tw-31e6a885d070}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2971\linewidth-2\tabcolsep}p{\dimexpr.3421\linewidth-2\tabcolsep}p{\dimexpr.3608\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Anti-CCP & \cAlignHack No. of Cases & \cAlignHack Percentage\\
\tblmidrule 
\cAlignHack Positive &
  \cAlignHack 73 &
  \cAlignHack 73\%\\
\cAlignHack Negative &
  \cAlignHack 27 &
  \cAlignHack 27\%\\
\cAlignHack Total &
  \cAlignHack 100 &
  \cAlignHack 100\%\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The majority of patients had positive Anti-CCP (73\%)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Deformities} }
\label{tw-69000ce353e1}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.311\linewidth-2\tabcolsep}p{\dimexpr.3196\linewidth-2\tabcolsep}p{\dimexpr.3694\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Deformities & \cAlignHack No. of Cases & \cAlignHack Percentage\\
\tblmidrule 
\cAlignHack Present &
  \cAlignHack 34 &
  \cAlignHack 34\%\\
\cAlignHack Absent &
  \cAlignHack 66 &
  \cAlignHack 66\%\\
\cAlignHack Total &
  \cAlignHack 100 &
  \cAlignHack 100\%\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{Deformities were presented in 34\% of patients}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Pulmonary Function Test} }
\label{tw-c27759fb6687}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2292\linewidth-2\tabcolsep}p{\dimexpr.26729999999999997\linewidth-2\tabcolsep}p{\dimexpr.2535\linewidth-2\tabcolsep}p{\dimexpr.25\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\multicolumn{2}{p{\dimexpr(.4965\linewidth-2\tabcolsep)}}{\cAlignHack Pulmonary Function Test } & \cAlignHack No. of Cases & \cAlignHack Percentage\\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.2292\linewidth-2\tabcolsep)}}{\multirow{3}{\linewidth}{\cAlignHack Day 1}} &
  \cAlignHack Normal &
  \cAlignHack 75 &
  \cAlignHack 75\%\\
 &
  \cAlignHack Obstructive &
  \cAlignHack 3 &
  \cAlignHack 3\%\\
 &
  \cAlignHack Restrictive &
  \cAlignHack 22 &
  \cAlignHack 22\%\\
\multicolumn{1}{p{\dimexpr(.2292\linewidth-2\tabcolsep)}}{\multirow{3}{\linewidth}{\cAlignHack 6 Months}} &
  \cAlignHack Normal &
  \cAlignHack 78 &
  \cAlignHack 78\%\\
 &
  \cAlignHack Obstructive &
  \cAlignHack 3 &
  \cAlignHack 3\%\\
 &
  \cAlignHack Restrictive &
  \cAlignHack 19 &
  \cAlignHack 19\%\\
\multicolumn{1}{p{\dimexpr(.2292\linewidth-2\tabcolsep)}}{\multirow{3}{\linewidth}{\cAlignHack 18 months}} &
  \cAlignHack Normal &
  \cAlignHack 85 &
  \cAlignHack 85\%\\
 &
  \cAlignHack Obstructive &
  \cAlignHack 3 &
  \cAlignHack 3\%\\
 &
  \cAlignHack Restrictive &
  \cAlignHack 12 &
  \cAlignHack 12\%\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{Chi-Square Value = 3.645; P-value = 0.456; Not Significant}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Correlation of duration of illness and pulmonary functional test (day 1)} }
\label{tw-f927f0355458}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1024\linewidth-2\tabcolsep}p{\dimexpr.0984\linewidth-2\tabcolsep}p{\dimexpr.26460000000000004\linewidth-2\tabcolsep}p{\dimexpr.1362\linewidth-2\tabcolsep}p{\dimexpr.13700000000000005\linewidth-2\tabcolsep}p{\dimexpr.12810000000000002\linewidth-2\tabcolsep}p{\dimexpr.1333\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} &  &  & \multicolumn{3}{p{\dimexpr(.4013000000000001\linewidth-2\tabcolsep)}}{\cAlignHack Pulmonary Functional Test (Day 1)} & \cAlignHack Total\\
\rowcolor{kwdboxcolor} &  &  & \cAlignHack Normal & \cAlignHack Obstructive & \cAlignHack Restrictive & \cAlignHack \\
\tblmidrule 
\cAlignHack  &
  \cAlignHack  &
  \cAlignHack Count &
  \cAlignHack 45 &
  \cAlignHack 0 &
  \cAlignHack 0 &
  \cAlignHack 45\\
\cAlignHack Duration of illness &
  \cAlignHack {\textless}5 years &
  \cAlignHack \% within Duration of illness &
  \cAlignHack 100.0\% &
  \cAlignHack .0\% &
  \cAlignHack .0\% &
  \cAlignHack 100.0\%\\
\cAlignHack  &
  \cAlignHack  &
  \cAlignHack Count &
  \cAlignHack 30 &
  \cAlignHack 3 &
  \cAlignHack 22 &
  \cAlignHack 55\\
\cAlignHack  &
  \cAlignHack {\textgreater}=5 years &
  \cAlignHack \% within Duration of illness &
  \cAlignHack 54.5\% &
  \cAlignHack 5.5\% &
  \cAlignHack 40.0\% &
  \cAlignHack 100.0\%\\
\cAlignHack Total &
  \cAlignHack  &
  \cAlignHack Count &
  \cAlignHack 75 &
  \cAlignHack 3 &
  \cAlignHack 22 &
  \cAlignHack 100\\
\cAlignHack  &
  \cAlignHack  &
  \cAlignHack \% within Duration of illness &
  \cAlignHack 75.0\% &
  \cAlignHack 3.0\% &
  \cAlignHack 22.0\% &
  \cAlignHack 100.0\%\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{Chi-Square Value = 27.273; P value = \textless\ 0.001; Significant }
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Correlation between DAS score and PFT result on day 1} }
\label{tw-fda98a027ff3}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.07660000000000004\linewidth-2\tabcolsep}p{\dimexpr.18720000000000002\linewidth-2\tabcolsep}p{\dimexpr.07660000000000003\linewidth-2\tabcolsep}p{\dimexpr.13190000000000003\linewidth-2\tabcolsep}p{\dimexpr.15270000000000003\linewidth-2\tabcolsep}p{\dimexpr.1328\linewidth-2\tabcolsep}p{\dimexpr.1284\linewidth-2\tabcolsep}p{\dimexpr.11379999999999999\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Pulmonary Functional Test (Day 1) & \cAlignHack N & \cAlignHack Mean & \cAlignHack Std. Deviation & \cAlignHack Std. Error Mean & \cAlignHack `t' value & \cAlignHack P-value\\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.07660000000000004\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{\cAlignHack DAS (Day 1)}} &
  \cAlignHack Obstructive &
  \cAlignHack 3 &
  \cAlignHack 6.1400 &
  \cAlignHack .80672 &
  \cAlignHack .46576 &
  \cAlignHack 0.986 &
  \cAlignHack 0.334\\
 &
  \cAlignHack Restrictive \mbox{}\protect\newline  &
  \cAlignHack 22 &
  \cAlignHack 5.7577 &
  \cAlignHack .61022 &
  \cAlignHack .13010 &
  \cAlignHack  &
  \cAlignHack \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The results show that there is no significant difference in the DAS score with respect to the pulmonary function test on day 1 (p=0.334)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Correlation between DAS score and PFT result on 6 months} }
\label{tw-1eee04e46001}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0802\linewidth-2\tabcolsep}p{\dimexpr.1926\linewidth-2\tabcolsep}p{\dimexpr.08719999999999999\linewidth-2\tabcolsep}p{\dimexpr.12\linewidth-2\tabcolsep}p{\dimexpr.12\linewidth-2\tabcolsep}p{\dimexpr.12\linewidth-2\tabcolsep}p{\dimexpr.12\linewidth-2\tabcolsep}p{\dimexpr.16\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} & \cAlignHack Pulmonary Functional Test (6 Months) & \cAlignHack N & \cAlignHack Mean & \cAlignHack Std. Deviation & \cAlignHack Std. Error Mean & \cAlignHack `t' value & \cAlignHack P-value\\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.0802\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{\cAlignHack DAS (6 Months) }} &
  \cAlignHack Obstructive  &
  \cAlignHack  3 &
  \cAlignHack  5.8800 &
  \cAlignHack  .86279 &
  \cAlignHack  .49813 &
  \cAlignHack  1.381 &
  \cAlignHack  0.183\\
 &
  \cAlignHack  Restrictive \mbox{}\protect\newline  &
  \cAlignHack  19 &
  \cAlignHack  5.3300 &
  \cAlignHack  .61173 &
  \cAlignHack  .14034 &
  \cAlignHack  &
  \cAlignHack \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The results show that there is no significant difference in DAS score with respect to pulmonary functional test after 6 months (p=0.183)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Correlation between DAS score and PFT result on 18months} }
\label{tw-fca25b4b182b}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0975\linewidth-2\tabcolsep}p{\dimexpr.16759999999999998\linewidth-2\tabcolsep}p{\dimexpr.0845\linewidth-2\tabcolsep}p{\dimexpr.1019\linewidth-2\tabcolsep}p{\dimexpr.1485\linewidth-2\tabcolsep}p{\dimexpr.1685\linewidth-2\tabcolsep}p{\dimexpr.11299999999999997\linewidth-2\tabcolsep}p{\dimexpr.1185\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Pulmonary Functional Test (18months) & \cAlignHack N & \cAlignHack Mean & \cAlignHack Std. Deviation & \cAlignHack Std. Error Mean & \cAlignHack `t' value & \cAlignHack P-value\\
\tblmidrule 
\multicolumn{1}{p{\dimexpr(.0975\linewidth-2\tabcolsep)}}{\multirow{2}{\linewidth}{\cAlignHack DAS (18 Months)}} &
  \cAlignHack  Obstructive &
  \cAlignHack  3 &
  \cAlignHack  5.5233 &
  \cAlignHack  .80649 &
  \cAlignHack  .46563 &
  \cAlignHack  1.792 &
  \cAlignHack  0.096\\
 &
  \cAlignHack  Restrictive \mbox{}\protect\newline  &
  \cAlignHack  12 &
  \cAlignHack  4.8675 &
  \cAlignHack  .51149 &
  \cAlignHack  .14765 &
  \cAlignHack  &
  \cAlignHack \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{The results show that there is no significant difference in DAS score with respect to pulmonary functional test after 18months (p=0.096)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Mean and SD of clinical parameters} }
\label{tw-5ba0b7719055}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2396\linewidth-2\tabcolsep}p{\dimexpr.20489999999999995\linewidth-2\tabcolsep}p{\dimexpr.27260000000000005\linewidth-2\tabcolsep}p{\dimexpr.2829\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Mean & \cAlignHack Std. Deviation & \cAlignHack Std. Error of Mean\\
\tblmidrule 
\cAlignHack ESR &
  \cAlignHack 66.29 &
  \cAlignHack 26.175 &
  \cAlignHack 2.617\\
\cAlignHack Hemoglobin &
  \cAlignHack 10.991 &
  \cAlignHack 1.4352 &
  \cAlignHack 0.1435\\
\cAlignHack DAS (Day 1) &
  \cAlignHack 5.4867 &
  \cAlignHack 0.68388 &
  \cAlignHack 0.06839\\
\cAlignHack DAS (6 Months) &
  \cAlignHack 4.6720 &
  \cAlignHack 0.91034 &
  \cAlignHack 0.09103\\
\cAlignHack DAS (18 Months) &
  \cAlignHack 3.6339 &
  \cAlignHack 1.16040 &
  \cAlignHack 0.11604\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\bgroup
\fixFloatSize{images/6ec220b3-3719-4e0e-a05b-ef2c20520083-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/6ec220b3-3719-4e0e-a05b-ef2c20520083-upicture1.png}{\includegraphics{images/6ec220b3-3719-4e0e-a05b-ef2c20520083-upicture1.png}}{}
\makeatother 
\caption{\boldmath {Pulmonary Function Test}}
\label{f-875f935cc429}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/cc33028b-8e4a-41bc-8f24-8fc920cb1357-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/cc33028b-8e4a-41bc-8f24-8fc920cb1357-upicture2.png}{\includegraphics{images/cc33028b-8e4a-41bc-8f24-8fc920cb1357-upicture2.png}}{}
\makeatother 
\caption{\boldmath {Correlation of duration of illness and pulmonary functional test (day 1)}}
\label{f-ff23be93d34d}
\end{figure}
\egroup
The chi-square test shows that there is a significant correlation between duration of illness and pulmonary functional test (day 1) (p\textless\ 0.001).

The present prospective study enrolled 100 patients diagnosed with Rheumatoid Arthritis (RA) who attended the Rheumatology Clinic at the Saveetha Medical College Hospital, Chennai, Tamilnadu, India with the objectives of defining their disease characteristics and ascertaining the prevalence of respiratory complications.

\textbf{Demographics}

The mean age group of the study population was 47.3 \ensuremath{\pm} 11.2 years. In the study population majority of patients were between 30-50 years (58\%). 35\% of patients were more than {\textgreater}50 years and 7\% of patients were less than {\textless}30 years (Table~\ref{tw-facc8f9cf44a}). The mean age of patients with pulmonary involvement was 50.6 \ensuremath{\pm} 9.4 years and the mean age of patients without pulmonary involvement was 46.7\ensuremath{\pm}11.4 years.

In the study population, female patients predominated over males, 89\% were females and 11\% were males (Table~\ref{tw-1374b2acf546}). The study was done by \unskip~\citep{708797:16804920}, and \unskip~\citep{708797:16804921} supported the finding of females were more than males.

\textbf{Characteristics of RA}

In the study group, the mean duration of illness was 6.4 \ensuremath{\pm} 5.5 years (Table~\ref{tw-3d76b6db3fc8}). In our group, 55\% of patients had a duration of more than 5 years and 45\% of patients had a duration of less than 5 years. 3\% of patients had a disease duration of less than one year (early RA). In our study, the mean duration of the disease of patients with RA with pulmonary complications was significantly longer (13.5 years vs. 5.3 years, p=0.00). The study done by \unskip~\citep{708797:16804912} from Baghdad showed a significant correlation between the duration of the disease and pulmonary complications. 

In our study group, 34\% of patients had deformities of RA (Table~\ref{tw-69000ce353e1}) reflecting the chronicity and inadequacy of therapy. 87\% of our patients were seropositive for the RA factor (Table~\ref{tw-d852d638b670}). In our study group, 73\% were positive for Anti CCP (Table~\ref{tw-31e6a885d070}).

\textbf{Pulmonary involvement}

This was assessed by pulmonary function tests (Table~\ref{tw-c27759fb6687}). 15\% of our patients had pulmonary complications. Pulmonary involvement was common in RA (Figure~\ref{f-875f935cc429}) and many studies reported that 1\% to 40\% of the patients were affected \unskip~\citep{708797:16804915}. In patients with RA, lung complications were the second most common of death (10\% to 20\%) after infection \unskip~\citep{708797:16804917}.\ensuremath{^{}}

Many studies published showed pulmonary involvement in patients with RA with lung physiology tests. The study by \unskip~\cite{708797:16804913} in 84 patients showed pulmonary involvement in 49\% of cases. The study by \unskip~\cite{708797:16804914} in 84 patients showed pulmonary involvement in 34.6\% of patients. The study by \unskip~\cite{708797:16804916} in 75 patients showed pulmonary involvement in 49.3\% of patients. The study by \unskip~\cite{708797:16804918} in 100 patients showed pulmonary involvement in 32\% of cases. The study by \unskip~\cite{708797:16804919} in 50 patients showed pulmonary involvement in 70\% of cases. The study by \unskip~\cite{708797:16804928} in 52 patients showed pulmonary involvement in 8.7\% of patients. In our study, lung involvement was found in 14\% of patients with RA. Interstitial lung disease and bronchiectasis were the commonest types of lung involvement in RA.

The incidence of lung involvement in the above-mentioned studies was higher than the rate in our study (15\%) (Table~\ref{tw-f927f0355458}), (Figure~\ref{f-ff23be93d34d}). These differences have been due to less disease duration, lower disease severity and a patient seeking treatment in the early phase. 

In our study, abnormalities in the pulmonary function test was a sensitive indicator for the diagnosis of a pulmonary complication of RA. HRCT thorax is also a sensitive test to identify pulmonary complications of RA. Therefore we suggest obtaining HRCT thorax and Pulmonary function tests at regular intervals in all patients with RA to help decide on aggressive therapy to delay the progression of the disease. 

In our study, the chi-square test shows that there is a significant correlation between duration of illness and pulmonary functional test (p\textless\ 0.001). The results show that there is no significant difference in the DAS score with respect to the pulmonary functional test (p=0.183) (Table~\ref{tw-fda98a027ff3},Table~\ref{tw-1eee04e46001}, Table~\ref{tw-fca25b4b182b}, Table~\ref{tw-5ba0b7719055}). 

 A population-based study by \unskip~\cite{708797:16804925} found a significant relationship between disease activity and ILD in RA patients. A study done by\unskip~\cite{708797:16804927} from Oman in 2009 found a significant relationship between disease activity and pulmonary involvement. 

We found no significant relation between pulmonary complications and characteristics like RA factor, ESR, smoking, hemoglobin and drugs like methotrexate and steroids (Table~\ref{tw-2f69782869cd}). Larger studies, including more number of patients with RA, is required to answer these relations. \unskip~\citep{708797:16804924}

\textbf{Limitations of this study}
  
  \begin{enumerate}
  \item \relax A small number of patients
  \item \relax Institution-based study
  \end{enumerate}
  
    
\section{Conclusion }
Pulmonary complications occur in patients with Rheumatoid Arthritis. Pulmonary involvement carries significant mortality and morbidity. Patients with RA should be evaluated with pulmonary function tests and HRCT thorax at regular intervals for early diagnosis and to delay the progression of the disease. In this study, Disease duration and disease activity score 28 were found to have a significant association with pulmonary complications. Larger studies, including more RA patients, are required to answer the relation of various other disease characteristics with pulmonary involvement. 
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
